Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <i>FLT3</i>-ITD.

RF, Schlenk; D, Weber; W, Fiedler; HR, Salih; G, Wulf; H, Salwender; T, Schroeder; T, Kindler; M, Lübbert; D, Wolf; J, Westermann; D, Kraemer; KS, Götze; HA, Horst; J, Krauter; M, Girschikofsky; M, Ringhoffer; T, Südhoff; G, Held; HG, Derigs; R, Schroers; R, Greil; M, Grießhammer; E, Lange; A, Burchardt; U, Martens; B, Hertenstein; L, Marretta; M, Heuser; F, Thol; VI, Gaidzik; W, Herr; J, Krzykalla; A, Benner; K, Döhner; A, Ganser; P, Paschka; H, Döhner

doi:10.1182/blood-2018-08-869453

Public

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

Shared by NobleBlocks on Dec 18, 2018 • 12:00 AM UTC

Authors:

Schlenk RF

Weber D

Fiedler W

Abstract

Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD) have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was conducted to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive chemotherapy followed ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!